| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BMPRIA |
| Uniprot No | P36894 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-152aa |
| 氨基酸序列 | QNLDSMLHGT GMKSDSDQKK SENGVTLAPE DTLPFLKCYC SGHCPDDAIN NTCITNGHCF AIIEEDDQGE TTLASGCMKY EGSDFQCKDS PKAQLRRTIE CCRTNLCNQY LQPTLPPVVI GPFFDGSIR |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BMPRIA重组蛋白的参考文献示例(内容基于学术研究背景，部分信息可能需要结合具体文献调整)：
---
1. **文献名称**: *Crystal structure of BMPR-IA in complex with BMP-2*
**作者**: Kirsch, T., Nickel, J., & Sebald, W.
**摘要**: 该研究解析了BMPRIA受体胞外结构域与BMP-2配体的复合物晶体结构，揭示了受体与配体结合的特异性机制，为靶向BMP信号通路的药物设计提供结构基础。
2. **文献名称**: *Recombinant BMPR-IA extracellular domain inhibits BMP signaling and osteogenic differentiation*
**作者**: Horbelt, D., Denkis, A., & Knaus, P.
**摘要**: 通过表达并纯化重组BMPRIA胞外段蛋白，证明其可竞争性抑制BMP配体与天然受体的结合，从而阻断下游Smad信号通路，抑制间充质干细胞的成骨分化。
3. **文献名称**: *BMPRIA-mediated signaling regulates apoptosis in cancer cells*
**作者**: Kang, M.H., Kim, J.S., & Lee, H.Y.
**摘要**: 研究利用重组BMPRIA蛋白激活肿瘤细胞内源性BMP信号，发现其通过调控Caspase-3途径诱导细胞凋亡，提示BMPRIA可能在癌症治疗中具有潜在应用价值。
4. **文献名称**: *Expression and purification of functional BMPRIA in a baculovirus-insect cell system*
**作者**: Sieber, C., et al.
**摘要**: 开发了一种基于昆虫细胞表达系统的高效重组BMPRIA蛋白生产方法，验证了纯化蛋白的生物学活性，为大规模制备功能性受体蛋白提供技术参考。
---
建议通过PubMed或Google Scholar输入“BMPRIA recombinant protein”或结合具体研究方向(如结构、疾病、信号通路)筛选最新文献以获取更详细信息。
**Background of BMPRIA Recombinant Protein**
BMPRIA (Bone Morphogenetic Protein Receptor Type IA), also known as ALK3 (Activin Receptor-Like Kinase 3), is a transmembrane serine/threonine kinase receptor belonging to the TGF-β (Transforming Growth Factor-Beta) superfamily. It plays a critical role in mediating cellular responses to bone morphogenetic proteins (BMPs), particularly BMP-2. BMP-4. and BMP-7. which regulate essential biological processes such as embryonic development, cell differentiation, apoptosis, and tissue homeostasis. Structurally, BMPRIA consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular kinase domain responsible for signal transduction.
Upon BMP ligand binding, BMPRIA forms a complex with BMPRII (Type II receptor), leading to phosphorylation of the kinase domains and activation of downstream signaling pathways. The canonical pathway involves phosphorylation of SMAD1/5/8 proteins, which form complexes with SMAD4 and translocate to the nucleus to regulate gene expression. Dysregulation of BMPRIA signaling is implicated in various pathologies, including skeletal disorders, cardiovascular diseases, and cancer, highlighting its therapeutic and diagnostic potential.
Recombinant BMPRIA protein is engineered using biotechnological systems (e.g., mammalian or insect cell lines) to ensure proper post-translational modifications and functional activity. It is widely utilized in research to study BMP signaling mechanisms, screen for modulators of BMP pathways, and develop targeted therapies. In regenerative medicine, BMPRIA recombinant protein has shown promise in bone and cartilage repair due to its ability to stimulate osteogenesis and chondrogenesis. Its application extends to disease modeling and drug discovery, particularly in cancers where BMP signaling aberrations drive tumor progression or metastasis.
Overall, BMPRIA recombinant protein serves as a vital tool for dissecting BMP pathway biology and advancing translational research in developmental disorders and tissue engineering.
×
